NASDAQ: MNKDMannkind Corp Stock
$3.54-0.04 (-1.12%)
Updated Sep 18, 2026
MNKD Price
$3.54
Fair Value Price
N/A
Market Cap
$1.14B
52 Week Low
$2.23
52 Week High
$6.51
P/E
-27.23x
P/B
-16.94x
P/S
3.35x
PEG
N/A
Dividend Yield
N/A
Revenue
$393.63M
Earnings
-$43.61M
Gross Margin
75.4%
Operating Margin
-0.05%
Profit Margin
-11.1%
Debt to Equity
-11.9
Operating Cash Flow
-$8M
Beta
1.12
Next Earnings
Nov 4, 2026
Ex-Dividend
N/A
Next Dividend
N/A
MNKD Overview
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MNKD's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MNKD
Ranked#260 of 461
Ranked#260 of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.60 | A | |
| $350.84 | A | |
| $42.02 | A |
Be the first to know about important MNKD news, forecast changes, insider trades & much more!
MNKD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MNKD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MNKD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MNKD is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
MNKD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more MNKD due diligence checks available for Premium users.
Valuation
MNKD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-27.23x
Industry
9.29x
Market
44.48x
MNKD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-16.94x
Industry
5.28x
MNKD's financial health
Profit margin
Revenue
$109.4M
Net Income
-$19.0M
Profit Margin
-17.4%
MNKD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MNKD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$732.3M
Liabilities
$799.5M
Debt to equity
-11.9
MNKD's short-term assets ($245.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MNKD's long-term liabilities ($656.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MNKD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MNKD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.4M
Investing
$17.9M
Financing
$559.0k
MNKD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MNKD vs Biotech Stocks
Mannkind Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.